Zydus cleared to begin US trial of oral therapy usnoflast for ALS
Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial testing its experimental oral treatment usnoflast in people with amyotrophic lateral sclerosis (ALS). The trial is expected to enroll 210 ALS patients. Each will receive one of two usnoflast…